Abstract:Coronary artery spasm (CAS) is an intense vasoconstriction of coronary arteries that causes total or subtotal vessel occlusion. The cardioprotective effect of sirtuin-1 (SIRT1) has been extensively highlighted in coronary artery diseases. The aims within this study include the investigation of the molecular mechanism by which SIRT1 alleviates CAS. SIRT1 expression was first determined by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and Western blot analysis in an endothelin-1 (ET-1)-induced rat CAS model. Interaction among SIRT1, nuclear factor-kappaB (NF-κB), myosin light chain kinase/myosin light chain-2 (MLCK/MLC2), and ET-1 was analyzed using luciferase reporter assay, RT-qPCR, and Western blot analysis. After ectopic expression and depletion experiments in vascular smooth muscle cells (VSMCs), contraction and proliferation of VSMCs and expression of contraction-related proteins (α-SMA, calponin, and SM22α) were measured by collagen gel contraction, 5-ethynyl-2'-deoxyuridine (EdU) assay, RT-qPCR, and Western blot analysis. The obtained results showed that SIRT1 expression was reduced in rat CAS models. However, overexpression of SIRT1 inhibited the contraction and proliferation of VSMCs in vitro. Mechanistic investigation indicated that SIRT1 inhibited NF-κB expression through deacetylation. Moreover, NF-κB could activate the MLCK/MLC2 pathway and upregulate ET-1 expression by binding to their promoter regions, thus inducing VSMC contraction and proliferation in vitro. In vivo experimental results also revealed that SIRT1 alleviated CAS through regulation of the NF-κB/MLCK/MLC2/ET-1 signaling axis. Collectively, our data suggested that SIRT1 could mediate the deacetylation of NF-κB, disrupt the MLCK/MLC2 pathway, and inhibit the expression of ET-1 to relieve CAS, providing a theoretical basis for the prospect of CAS treatment and prevention.NEW & NOTEWORTHY Rat coronary artery spasm models exhibit reduced expression of SIRT1. Overexpression of SIRT1 inhibits contraction and proliferation of VSMCs. SIRT1 inhibits NF-κB through deacetylation to modulate VSMC contraction and proliferation. NF-κB activates the MLCK/MLC2 pathway. NF-κB upregulates ET-1 to modulate VSMC contraction and proliferation.

Evaluation of Therapeutic Agents Targeting the Pathogenesis of Coronary Artery Spasm: A Mini Review.

Evaluation Of Therapeutic Agents Targeting The Pathogenesis Of Coronary Artery Spasm: A Mini Review

Aberrant Endoplasmic Reticulum Stress Mediates Coronary Artery Spasm Through Regulating MLCK/MLC2 Pathway

The Angiographic Findings of Coronary Arterial Spasm (A Report of 37 Cases)

Vasospastic angina: Past, present, and future

SIRT1-mediated deacetylation of NF-κB inhibits the MLCK/MLC2 pathway and the expression of ET-1, thus alleviating the development of coronary artery spasm

TLR4-Myd88 pathway upregulated caveolin-1 expression contributes to coronary artery spasm

Coronary Spasm Testing with Acetylcholine: A Powerful Tool for a Personalized Therapy of Coronary Vasomotor Disorders

Unusual Recurrent Multivessel Coronary Artery Spasm: A Case Report and Literature Review

Vasospastic angina: a review on diagnostic approach and management

Diagnosis and treatment of coronary spasm in China: a case report

Comparison of various calcium antagonist on vasospastic angina: a systematic review

Characterization and implications of intracoronary hemodynamic assessment during coronary spasm provocation testing

Immunomodulatory Mechanism of Coronary Heart Disease and Related Therapeutic Applications and Prospects

Pathogenesis, Assessment, and Treatment of Coronary Microcirculation Dysfunction.

Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications

Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions

A review of methods for assessment of coronary microvascular disease in both clinical and experimental settings

Alternate Recurrent Coronary Artery Spasm and Stress Cardiomyopathy: a Case Report

Efficacy of BAY 60-2770, a Soluble Guanylate Cyclase Activator, for Coronary Spasm in Animal Models

New Concepts on the Pathophysiology of Acute Coronary Syndrome